GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Myomo Inc (AMEX:MYO) » Definitions » Beneish M-Score

Myomo (MYO) Beneish M-Score : -3.11 (As of May. 12, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Myomo Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.11 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Myomo's Beneish M-Score or its related term are showing as below:

MYO' s Beneish M-Score Range Over the Past 10 Years
Min: -3.11   Med: -2.22   Max: -0.55
Current: -3.11

During the past 8 years, the highest Beneish M-Score of Myomo was -0.55. The lowest was -3.11. And the median was -2.22.


Myomo Beneish M-Score Historical Data

The historical data trend for Myomo's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myomo Beneish M-Score Chart

Myomo Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial -3.02 -2.22 - -1.21 -3.11

Myomo Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.21 -2.85 -2.85 -2.65 -3.11

Competitive Comparison of Myomo's Beneish M-Score

For the Medical Devices subindustry, Myomo's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myomo's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Myomo's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Myomo's Beneish M-Score falls into.



Myomo Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Myomo for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0161+0.528 * 0.9611+0.404 * 0.2628+0.892 * 1.237+0.115 * 1.1418
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8232+4.679 * -0.123646-0.327 * 1.025
=-3.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $2.38 Mil.
Revenue was 4.756 + 5.08 + 5.959 + 3.447 = $19.24 Mil.
Gross Profit was 3.105 + 3.489 + 4.281 + 2.308 = $13.18 Mil.
Total Current Assets was $13.65 Mil.
Total Assets was $14.58 Mil.
Property, Plant and Equipment(Net PPE) was $0.84 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.52 Mil.
Selling, General, & Admin. Expense(SGA) was $18.78 Mil.
Total Current Liabilities was $5.48 Mil.
Long-Term Debt & Capital Lease Obligation was $0.12 Mil.
Net Income was -2.46 + -2.029 + -1.014 + -2.644 = $-8.15 Mil.
Non Operating Income was -0.064 + -0.071 + -0.018 + -0.017 = $-0.17 Mil.
Cash Flow from Operations was -2.356 + -1.715 + -0.286 + -1.817 = $-6.17 Mil.
Total Receivables was $1.90 Mil.
Revenue was 4.042 + 3.968 + 3.678 + 3.868 = $15.56 Mil.
Gross Profit was 2.628 + 2.637 + 2.401 + 2.577 = $10.24 Mil.
Total Current Assets was $9.22 Mil.
Total Assets was $10.16 Mil.
Property, Plant and Equipment(Net PPE) was $0.70 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.54 Mil.
Selling, General, & Admin. Expense(SGA) was $18.44 Mil.
Total Current Liabilities was $3.60 Mil.
Long-Term Debt & Capital Lease Obligation was $0.20 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.383 / 19.242) / (1.896 / 15.556)
=0.123844 / 0.121882
=1.0161

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(10.243 / 15.556) / (13.183 / 19.242)
=0.65846 / 0.685116
=0.9611

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (13.651 + 0.839) / 14.582) / (1 - (9.215 + 0.703) / 10.162)
=0.006309 / 0.024011
=0.2628

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=19.242 / 15.556
=1.237

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.542 / (0.542 + 0.703)) / (0.517 / (0.517 + 0.839))
=0.435341 / 0.381268
=1.1418

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(18.778 / 19.242) / (18.442 / 15.556)
=0.975886 / 1.185523
=0.8232

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.115 + 5.477) / 14.582) / ((0.2 + 3.602) / 10.162)
=0.383486 / 0.374139
=1.025

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-8.147 - -0.17 - -6.174) / 14.582
=-0.123646

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Myomo has a M-score of -3.11 suggests that the company is unlikely to be a manipulator.


Myomo (MYO) Business Description

Traded in Other Exchanges
Address
137 Portland Street, 4th Floor, Boston, MA, USA, 02114
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the device to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
Executives
Thomas F Kirk director
Milton Mayo Morris director 2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Paul R Gudonis director, officer: Chief Executive Officer 9 HICKORY ROAD, MANCHESTER MA 01944
David A Henry officer: Chief Financial Officer
Harry Kovelman officer: Chief Medical Officer C/O MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Yitzchak Jacobovitz director MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Micah Mitchell officer: Chief Commercial Officer C/O MYOMO, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02139
Crowley Thomas Aloysius Jr. director 19 ST CLAIR AV, SPRING LAKE NJ 07762
Cliff Conneighton officer: Chief Marketing Officer 53 DEPOT ROAD, HOLLS NH 03049
Jonathan Naft officer: VP, General Manager C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Brandon M Green officer: Chief Medical Officer C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ralph A Goldwasser officer: Chief Financial Officer BNN CORP, 150 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Davie Mendelsohn officer: VP, Sales C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Steve Sanghi director 2355 W CHANDLER BLVD, CHANDLER AZ 85224-6199
Amy K. Knapp director 75 N. MOUNTAIN AVE, MONTCLAIR NJ 07042